Abstract
Cancer costs the life of over 6 M human beings from around the world every year. More than 1.3 million new cases are predicted to be diagnosed only in the USA during 2005 with over 570,000 deaths estimated. A better understanding of the molecular basis of carcinogenesis has facilitated progress towards improving early detection and prevention as well as the development of more efficient and specific treatments against certain types of cancer. However, very few successful anticancer agents exist today and aggressive tumors are still incurable. Retinoids are natural and synthetic derivatives of vitamin A, which have shown promise for the prevention and treatment of cancer because of their cell growth inhibition and differentiation activities. Unfortunately, their clinical use has been stalled by significant toxicity caused by the broad biological responses mediated by the nuclear retinoid receptors. Synthetic retinoid-related molecules containing an adamantyl group have been shown to induce apoptosis and show promising anticancer activity in animal models, therefore representing optimal leads for the development of novel retinoid-like anticancer drugs. These compounds induce apoptosis via the mithochondrial pathway and seem to function independently of nuclear retinoid receptor activity. In contrast, they have an effect on various cytosolic signaling pathways, including activation of stress kinases (cJun N-terminal kinase and p38 kinase) and inhibition of survival kinases (I κB kinase).
Keywords: Atypical retinoids, adamantyl retinoid-related molecules, nuclear retinoid receptors, apoptosis, stress kinases, I κB kinase inhibitor
Current Cancer Therapy Reviews
Title: Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules
Volume: 2 Issue: 2
Author(s): F. J. Piedrafita and Maria A. Ortiz
Affiliation:
Keywords: Atypical retinoids, adamantyl retinoid-related molecules, nuclear retinoid receptors, apoptosis, stress kinases, I κB kinase inhibitor
Abstract: Cancer costs the life of over 6 M human beings from around the world every year. More than 1.3 million new cases are predicted to be diagnosed only in the USA during 2005 with over 570,000 deaths estimated. A better understanding of the molecular basis of carcinogenesis has facilitated progress towards improving early detection and prevention as well as the development of more efficient and specific treatments against certain types of cancer. However, very few successful anticancer agents exist today and aggressive tumors are still incurable. Retinoids are natural and synthetic derivatives of vitamin A, which have shown promise for the prevention and treatment of cancer because of their cell growth inhibition and differentiation activities. Unfortunately, their clinical use has been stalled by significant toxicity caused by the broad biological responses mediated by the nuclear retinoid receptors. Synthetic retinoid-related molecules containing an adamantyl group have been shown to induce apoptosis and show promising anticancer activity in animal models, therefore representing optimal leads for the development of novel retinoid-like anticancer drugs. These compounds induce apoptosis via the mithochondrial pathway and seem to function independently of nuclear retinoid receptor activity. In contrast, they have an effect on various cytosolic signaling pathways, including activation of stress kinases (cJun N-terminal kinase and p38 kinase) and inhibition of survival kinases (I κB kinase).
Export Options
About this article
Cite this article as:
Piedrafita J. F. and Ortiz A. Maria, Mechanism of Action and Therapeutic Potential of Novel Adamantyl Retinoid-Related Molecules, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872852
DOI https://dx.doi.org/10.2174/157339406776872852 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Occurrence and Severity of Adverse Reactions of Immune Checkpoint Inhibitors (PD-1 and PD L1) Based on Mordovian Dispensary Data Analysis
Current Cancer Therapy Reviews Plant Natural Products in Anticancer Drug Discovery
Current Organic Chemistry Cyclooxygenase-2 (COX-2) Mediates Arsenite Inhibition of UVB-Induced Cellular Apoptosis in Mouse Epidermal Cl41 Cells
Current Cancer Drug Targets Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Current Pharmaceutical Design New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Current Pharmaceutical Design Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Photodynamic Inactivation of Bacteria
Current Bioactive Compounds Synthesis and Antitumor Evaluation of Thiophene Analogs of Kigelinone
Letters in Organic Chemistry Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Role of Thymidine Phosphorylase in Biomodulation of Fluoropyrimidines
Current Pharmaceutical Biotechnology